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Abstract Fas Ligand (FasL) expression by cancer cells
may contribute to tumour immune escape via the Fas
counterattack against tumour-infiltrating lymphocytes
(TILs). Whether this plays a role in colorectal carcinogenesis
in Lynch syndrome was examined studying FasL expression,
tumour cell apoptosis and number of TILs in colorectal
neoplasms from Lynch syndrome patients (50 adenomas, 20
carcinomas) compared with sporadic cases (69 adenomas, 52
carcinomas). FasL expression was observed in 94% of Lynch
syndrome adenomas and in all carcinomas. FasL expression
patterns and apoptotic indices were similar in Lynch syn-
drome-associated neoplasms and sporadic cases. The number
of TILs was higher in Lynch syndrome neoplasms than in
sporadic cases. There were no correlations between FasL
expression and tumour cell apoptosis or number of TILs in
Lynch syndrome-associated neoplasms. So, FasL expression
is an early event in Lynch syndrome and sporadic colorectal
carcinogenesis, but not related to TIL number. Taken together,
our data do not support a role for the Fas counterattack in
colorectal carcinogenesis in Lynch syndrome.
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HNPCC hereditary nonpolyposis colorectal cancer
MSI microsatellite instability
MSS microsatellite stable
TNF tumour necrosis factor
WHO World Health Organization
Introduction
Lynch syndrome (LS), or hereditary nonpolyposis colorectal
cancer (HNPCC), is characterised by an autosomal dominant
inheritance of early-onset colorectal cancer and an increased
risk of other cancers, in particular cancer of the endometrium
[1]. LS is caused by germline mutations in a mismatch
repair gene, mostly hMLH1, hMSH2 and hMSH6 [1].
These genes encode proteins involved in DNA repair.
Failure of the DNA mismatch repair machinery to repair
errors occurring during DNA replication leads to increased
length variation of simple, repetitive sequences distributed
throughout the genome, so-called microsatellite instability
(MSI). An international set of markers is developed to test
for MSI. Tumours are scored MSI-high if at least 30% of
the markers show instability, MSI-low if less than 30%
show instability, or MS-stable (MSS) if none of the markers
shows instability [2]. The MSI-H phenotype is found in up
to 92% of colorectal cancers associated with LS and in 10–
15% of sporadic colorectal cancers [1].
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Dysfunction of one of the mismatch repair genes results
in a rapid accumulation of genetic alterations in susceptible
genes, including genes involved in growth suppression,
apoptosis and signal transduction [1]. These alterations
contribute to an accelerated adenoma–carcinoma sequence in
LS compared to sporadic cancer. This is illustrated by the
relative frequent occurrence of interval cancers between
regular surveillance colonoscopies [3, 4]. In addition, LS
adenomas frequently harbour a villous component and high-
grade dysplasia, both markers of increased cancer risk [5, 6].
Among the genes that are targeted in the setting of MSI are
BAX and caspase 5, suggesting that disturbances in
apoptosis regulation may be important as a mechanism
behind the accelerated colorectal carcinogenesis in LS [7, 8].
Apoptosis can be either initiated by the cell itself or by
certain external stimuli. These external stimuli may induce
apoptosis by targeting one of two pathways [7]. The
‘extrinsic’ pathway is initiated by triggering cell death
receptors on the cell surface, leading to activation of the
intracellular apoptotic machinery. The ‘intrinsic’ pathway
of apoptosis is initiated via the mitochondria by cellular
stress, such as chemotherapeutic drugs and radiation. Fas is
a protein of the tumour necrosis factor (TNF) receptor
superfamily, known to induce apoptosis through the
extrinsic pathway in sensitive cells by binding to its natural
ligand, Fas Ligand (FasL). In the normal human colon, all
epithelial cells express Fas, but not FasL [9]. In contrast,
many colorectal carcinomas and some adenomas show
FasL expression [10–13]. It has been hypothesized that
FasL expression in tumour cells might enable these cells to
evade immune destruction by inducing apoptosis in
tumour-infiltrating lymphocytes (TILs), a concept which
has become known as the Fas counter-attack [14]. In a
previous study, FasL expression was reported to be higher
in MSI-H colorectal cancers compared to MSI-L and MSS
cancers [15]. To date, FasL expression has not been
examined in colorectal tumours from LS patients. We
hypothesized that a diminished Fas counterattack between
LS and sporadic colorectal tumours play a role as a
mechanism to explain the difference in carcinogenesis.
Therefore, FasL expression, tumour cell apoptosis and
number of TILs in colorectal neoplasms from LS patients
in comparison with sporadic cases were studied.
Materials and Methods
Patients
Lynch Syndrome At theUniversityMedical Centre Groningen,
patients with a germline mismatch repair gene mutation and/or
fulfilling the Amsterdam II criteria undergo colonoscopy every
1–2years starting at the age of 25years, according to the current
surveillance guidelines [1]. All colorectal adenomas and
carcinomas removed in these patients over a period of 23years
with sufficient material available to allow serial sectioning for
immunohistochemistry were selected for this study. In total, 20
carcinomas were examined, 17 from proven mutation carriers
(8 hMLH1, 7 hMSH2, 2 hMSH6), as determined by
sequencing of genomic DNA, and three from patients with a
family history fulfilling the Amsterdam II criteria. Fifty
adenomas, 23 from proven mutation carriers, 27 from patients
with a family history fulfilling the Amsterdam II criteria, were
analyzed.
Sporadic cases The control group consisted of sporadic
carcinomas from a previously reported cohort of 500
patients with stage III colon cancer [16]. From this cohort,
in which MSI analysis has been performed, we selected all
MSI-H tumours (n = 26) and randomly 26 MSS tumours.
MSI-H tumours were included to determine possible
differences between sporadic MSI-H tumours and LS-
associated tumours which also are characterized by the MSI-
H phenotype. None of the 26 patients with a MSI-H tumour
was known with a MMR gene mutation or had a family
history fulfilling the Amsterdam II criteria, so these were
considered truly sporadic cases. Sporadic adenomas of which
sufficient material was available to allow serial sectioning for
immunohistochemical staining were selected from a previ-
ously described series [17] as control adenomas (n = 69).
Histologic classifications were carried out on haematox-
ylin and eosin stained slides. The morphological classifica-
tion of the carcinomas and adenomas was conducted
according to the World Health Organization (WHO) criteria
[18]. Adenocarcinomas were graded into well, moderately
and poorly differentiated. For statistical purposes, tumours
with good and moderate differentiation were compared with
tumours with poor differentiation. From adenomas, the
circumferential size was measured, and the severity of
dysplasia was expressed as low- or high-grade. Adenomas
were classified as tubular, tubulovillous or villous [18]. For
statistical purposes, tubulovillous and villous adenomas
were taken together.
Immunohistochemistry
For immunohistochemical staining for FasL, sections were
deparaffinized in xylene, rehydrated through decreasing
concentrations of alcohol and finally in phosphate-buffered
saline. For antigen retrieval, slides were subjected to steam-
heat for 30min, using a commercially available steamer.
After washing with PBS, sections were incubated with
avidin and biotin blocking solutions (Vector Laboratories,
Burlingame, CA, USA), followed by incubation for 1h at
room temperature with a monoclonal anti-FasL antibody
(MAb33, Transduction Laboratories, Lexington, KY, USA)
400 J.J. Koornstra et al.
in a 1:300 dilution. After washing with PBS, slides were
incubated with a 1:300 dilution of a biotinylated rabbit-anti-
goat antibody (DAKO, Glostrup, Denmark), followed by
addition of streptavidin-conjugated peroxidase (DAKO).
Peroxidase activity was visualized with diaminobenzidine.
Counterstaining was performed with haematoxylin. As
negative controls, slides were immunostained in the
absence of the primary antibody, and in these cases no
immunostaining was detected. Evaluation of staining was
performed by two independent investigators, without
knowledge of the histopathological data. The percentage
of positive cells was estimated and scored on a semiquan-
titative scale as (1) 0–25%, (2) 26–50%, (3) 51–75%, (4)
76–100%, in accordance with others [14, 15].
Apoptosis in epithelial cells was determined by immu-
nohistochemistry with the murine monoclonal antibody
M30 (Boehringer Mannheim, Mannhein, Germany), which
reacts with a cleavage product of cytokeratin 18, released
by activated caspase [19]. The immunoreactivity of the
M30 antibodies is confined to the cytoplasm of apoptotic
cells and is present during early apoptosis [20]. M30
staining has been shown to correlate well with the gold
standard of morphological criteria [17]. Staining procedures
for M30 were performed as described before [17].
Apoptosis was assessed in at least 1,000 tumour cells and
expressed as a percentage of the total number of cells
counted (apoptotic index). M30 positivity was identified as
brown cytoplasmic staining.
The presence of TILs was assessed using a monoclonal
antibody against CD8. Antigen retrieval was performed by
immersing slides in 1mM EDTA buffer (pH 8.0) and
heating in a microwave oven for 8min. The primary
antibody (DAKO) was applied in a 1:50 solution for 1h
followed by a secondary rabbit-anti-mouse antibody conju-
gated with peroxidase (DAKO) and a tertiary goat-anti-
rabbit peroxidase-conjugated antibody.
For each tumour, the number of intraepithelial CD8+
cells was determined in ten high power fields (400 ×
magnification), in accordance with other studies [15, 21,
22]. TILs were defined as intraepithelial rather than peri-
tumoural or stromal lymphocytes.
Statistical Analysis
Statistical significance of differences between LS and
sporadic cases was tested using the Mann-Whitney test for
continuous variables and chi-square tests for discontinuous
variables. To test the relationship between increasing FasL
expression and continuous variables as apoptotic index and
CD8 counts, the Wilcoxon rank sum test was used. P-values
<0.05 were considered significant. SPSS for Windows
software (SPSS Inc., Chicago, IL, USA) was used.
Results
Tumour Characteristics
Patient and tumour characteristics are summarized in Table 1.
Inherent to the patient groups, several differences were
observed between groups. Mean age of LS patients at the
time of adenoma removal was lower than for those with
sporadic disease (p < 0.0001). LS-associated adenomas were
smaller (p = 0.002), more often containing high-grade
dysplasia (p < 0.01) and more often proximally localized
(p < 0.05), i.e. proximal to the splenic flexure, compared with
their sporadic counterparts. LS-associated carcinomas and
MSI-H sporadic carcinomas were more often localized in the
proximal colon compared to sporadic MSS cases, (p < 0.001).
FasL Expression in LS and Sporadic Colorectal Neoplasms
Staining results are summarized in Table 2. FasL expression
in epithelial cells was seen in 47/50 LS-associated
adenomas and 64/69 sporadic adenomas (not significantly
different). FasL expression was cytoplasmic and generally
Table 1 Patient and tumour characteristics
Adenomas Carcinomas
LS Sporadic LS Sporadic MSS Sporadic MSI-H
n 50 69 20 26 26
Male (%) 48 30 85 73 69
Age in yrs (mean, range) 49 (30–67) 66 (28–89) 54 (31–77) 59 (40–75) 60 (26–76)
Size in mm (mean, range) 6.9 (2–30) 10.2 (3–45)
Proximal localisation (%) 42 26 65 39 81
Pathology
Tubular (%) 54 54
High-grade dysplasia (%) 46 26
Poor differentiation (%) 25 12 15
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heterogeneously distributed within adenomatous tissue. In
both groups, approximately half of the samples displayed
expression in more than 50% of tumour cells. The extent of
FasL positivity was not related to age, gender, adenoma
size, location, degree of dysplasia or villous architecture,
neither in LS-associated, nor in sporadic cases.
In carcinomas, FasL expression was present in all
samples investigated. FasL expression was generally
heterogeneously distributed. Percentages of positively
staining cells were similar in LS, MSS and MSI-H sporadic
tumours. In all three groups, approximately 80% of cases
demonstrated FasL expression in more than 50% of cells.
FasL expression was not related to age, gender, tumour
location or degree of differentiation. When comparing FasL
expression in adenomas and carcinomas, it was similar in
LS-associated neoplasms (Fig. 1). In sporadic cases,
percentages of positively staining cells were higher in
carcinomas than in adenomas (p < 0.001). This was true for
MSS carcinomas as well as for MSI-H carcinomas.
Tumour Cell Apoptosis and Number of TILs in LS
and Sporadic Colorectal Neoplasms
The level of tumour cell apoptosis, assessed by M30
immunoreactivity (Fig. 2), was similar between LS and
sporadic adenomas, although there was a non-significant
trend towards higher levels in LS adenomas (p = 0.08). The
same trend was observed in LS carcinomas, with apoptotic
indices being slightly higher than in sporadic cancers (p = 0.07).
When comparing carcinomas with adenomas, mean apoptotic
indices were higher in carcinomas, both in LS (p < 0.05) and
in sporadic cases (p < 0.001).
The number of TILs, assessed by CD8 positivity, was
higher in LS adenomas compared with sporadic adenomas
(p < 0.05, Fig. 3). Within the group of LS adenomas, the
mean number of TILs was higher in adenomas with high-
grade dysplasia compared with those with low-grade
dysplasia (8.8 ± 1.8 vs 4.7 ± 0.8, p < 0.001). The mean
number of TILs was also higher in adenomas with proximal
location compared with those with distal location (9.4 ± 1.9
vs 4.7 ± 0.8, p < 0.001). The mean number of TILs was not
correlated with adenoma size or the presence of villous
Fig. 1 FasL expression (brown) in colorectal carcinomas with
adjacent normal mucosa. A, Cancer associated with Lynch syndrome;
B, Sporadic cancer. In both cases, stronger expression of FasL in
tumour cells was seen compared to normal cells (magnification × 100)
Table 2 FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and
carcinomas
Adenomas Carcinomas
LS Sporadic LS Sporadic MSS Sporadic MSI-H
n 50 69 20 26 26
n FasL + (%) 47 (94) 64 (93) 20 (100) 26 (100) 26 (100)
0–25% 17 (34) 35 (51) 3 (15) 2 (8) 4 (15)
26–50% 4 (8) 9 (13) 1 (5) 1 (4) 2 (8)
51–75% 9 (18) 10 (14) 6 (30) 1 (4) 3 (12)
76–100% 20 (40) 15 (22) 10 (50) 22 (84)# 17 (65)#
AI (mean ± SEM) 1.1±0.22 0.4±0.05 1.5±0.38¶ 1.0±0.19* 1.1±0.28*
TILs (mean ± SEM) 6.6±0.96 3.9±0.38## 18.6±4.84¶¶ 6.6±1.27 23.9±6.60**
#P<0.001 for sporadic carcinomas vs sporadic adenomas; ¶ p<0.05 for LS carcinomas vs LS adenomas; * p<0.001 for sporadic carcinomas vs
sporadic adenomas; ## p<0.05 for LS adenomas vs sporadic adenomas; ¶¶ p=0.01 for LS carcinomas versus sporadic MSS carcinomas and <0.001
for LS carcinomas vs LS adenomas; ** p=0.02 for sporadic MSI-H vs sporadic MSS carcinomas.
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architecture in LS adenomas. In sporadic adenomas, the
number of TILs was not correlated with adenoma size,
degree of dysplasia, architecture or location.
In carcinomas, the number of TILs was similar in LS-
associated carcinomas and MSI-H sporadic cancers but
higher in both these groups than in MSS sporadic tumours
(p = 0.01 and 0.02 respectively, Fig. 3). In LS-associated
tumours, TIL density was higher in carcinomas than in
adenomas (p < 0.001). There was no correlation between
the number of TILs and tumour location or degree of
differentiation. This was the case in LS-associated cancers
as well as in sporadic cancers.
Relationship Between FasL Expression, Tumour Cell
Apoptosis and TILs
To search support for the FasL counterattack hypothesis, we
determined whether higher FasL expression in neoplasms
was associated with lower levels of tumour cell apoptosis or
reduced TIL densities (Table 3). For this analysis, adeno-
mas and carcinomas from LS patients and were taken
together as well as adenomas and MSS carcinomas from
sporadic origin. In LS-associated cases, there were no
positive or negative correlations between the percentage of
FasL positivity on the one hand and levels of tumour cell
apoptosis or number of TILs on the other. There was also
no correlation between the degree of tumour cell apoptosis
and the number of TILs. In contrast, in sporadic cases, there
Fig. 3 Staining of tumour-infiltrating lymphocytes (TILs) by CD8
immunoreactivity (brown). A, Lynch syndrome associated cancer; B,
Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D,
Sporadic adenoma. The number of TILs is higher in cases associated with
Lynch syndrome compared to sporadic ones (magnification × 400)
Fig. 2 Example of M30 immunoreactivity in colon cancer, showing
three cells with brown cytoplasmic staining (magnification × 100)
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was a positive correlation between higher FasL expression
and degree of tumour cell apoptosis (Spearman’s rho
correlation coefficient 0.27, p=0.008). There was no
correlation between FasL expression and the number of
TILs, nor between the degree of tumour cell apoptosis and
the number of TILs in sporadic neoplasms.
Discussion
In this study, we sought to determine whether the Fas
counterattack plays a role in the accelerated colorectal
carcinogenesis in LS patients compared to sporadic disease.
We found no support for such a mechanism, as FasL
expression was similar between LS and sporadic tumours.
In addition, there were no correlations between the percen-
tages of FasL positivity and the number of TILs. A novel
finding from our study was that LS-associated adenomas, in
addition to LS-associated carcinomas, are also characterized
by higher numbers of TILs compared to sporadic cases.
Colorectal carcinogenesis in LS is believed to be
accelerated when compared with sporadic cases. This is
illustrated by the relative frequent occurrence of interval
cancers between regular surveillance colonoscopies. In
addition, LS-associated adenomas frequently harbour villous
components and high-grade dysplasia, which both are
markers of increased cancer risk. Differences between LS
and sporadic colorectal neoplasms have been extensively
studied, demonstrating differences in molecular genetic
alterations [23–26] and histopathological characteristics [6,
15, 27, 28]. The accelerated carcinogenesis in LS does not
seem to be reflected by a difference in degree of apoptosis
with sporadic carcinogenesis [29, 30], although several
differences in expression of apoptosis-regulating proteins
have been found [30, 31, 32]. To our knowledge, FasL
expression has not been studied before in LS-associated
neoplasms. Our results indicate similar expression patterns
of FasL in LS and sporadic neoplasms. So, FasL expression
seems to occur early in colorectal carcinogenesis, irrespec-
tive of the sporadic or hereditary origin of the lesions.
We found that FasL expression was more prevalent in
carcinomas than in adenomas, consistent with other reports [10–
13]. It was recently demonstrated that MSI-H tumours were
associated with a reduced frequency of FasL expression relative
to non-MSI-H tumours [33]. In our study, a similar trend was
seen although this did not reach statistical significance.
Infiltration of lymphocytes is a prominent feature of
MSI-H tumours, including LS-associated colorectal cancer
[21, 22, 27, 34]. This was confirmed in the present report.
In this study, we show for the first time that LS-associated
adenomas display the same feature. Moreover, we found
that the mean number of TILs was higher in LS adenomas
with high-grade dysplasia compared with those with low-
grade dysplasia. Only few studies are available that have
evaluated the degree of infiltration with lymphocytes in
adenomas [35–37]. From these studies, it appears that the
number of TILs increases in the course of the adenoma-
carcinoma sequence, which is corresponding to our results.
It has also been shown that the number of TILs is an
independent prognostic factor in colorectal cancer [38–40].
As LS-associated colorectal cancer and sporadic MSI-H
colorectal cancer are associated with better survival rates
than sporadic cases [1], it has been suggested that the
presence of a cytotoxic anti-tumour immune response may
at least in part contribute to the survival advantage
described in these patients [34, 38]. Whether TILs in LS-
associated and MSI-H sporadic tumours are really activated
cytotoxic T-cells remains to be demonstrated.
The aim of our study was to determine whether higher
FasL expression in neoplasms was associated with lower
levels of tumour cell apoptosis or increased levels of
apoptotic TILs, reflected by reduced TIL density. We found
no such correlations in LS-associated neoplasms. In
sporadic cases, a positive rather than a negative correlation
between FasL expression and tumour cell apoptosis was
found. This finding may be a consequence of elevated FasL
levels triggering tumour cell apoptosis in a manner similar
to autocrine suicide of activated T-cells [41]. Our findings
are in contrast with those from Houston et al, who did not
find a correlation between FasL expression and degree of
Table 3 Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean ± SEM) and TILs (mean ± SEM) in
LS and sporadic colorectal neoplasms
LS adenomas and carcinomas Sporadic adenomas and MSS carcinomas
n AI TILs n AI TILs
FasL expression
0–25% 20 0.99±0.25 6.7±1.5 39 0.43±0.07 3.4±0.4
26–50% 5 1.84±1.28 10.7±4.7 11 0.68±0.19 5.3±1.9
51–75% 17 1.45±0.48 11.9±4.8 13 0.47±0.09 3.9±0.8
76–100% 28 1.13±0.27 11.1±2.7 32 0.82±0.15 6.3±1.0
Total 70 1.22±0.19 10.0±1.65 95 0.59±0.07 4.7±0.5
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tumour cell apoptosis [42]. It must be noted that their series
consisted of only ten colorectal tumours, which may
explain the absence of a correlation in their study. The same
research group recently found a non-significant negative
association between intensity of FasL staining and number of
TILs in a series of 91 colon carcinomas [43]. Two studies
reported a positive correlation between FasL expression and
apoptosis in TILs [43, 44], whereas we did not find an
association between FasL expression and TIL density. The
background for the discrepancy between these data and ours
is unclear. A possible explanation may lie in the fact that in
the other studies TUNEL and ISNT were used to assess TIL
apoptosis. Both these techniques have poor specificity
for apoptosis and their use is currently discouraged
[7, 45].
The question whether the Fas counterattack plays a role
at all in colorectal carcinogenesis is surrounded with
controversy [46, 47]. The idea behind the concept is that
FasL expression by tumour cells may enable those cells to
kill anti-tumour immune effector T-cells that infiltrate the
tumour. Many tumours and tumour cell lines of varying
histologic origin express FasL [48]. Several functional
studies have shown that FasL positive colon tumour cells
can induce apoptosis of Fas-sensitive lymphocytes in vitro
[49, 50]. In addition, inhibition of FasL expression reduced
tumour development and growth in a xenograft experiment
[51]. There are however also experimental data which
seriously question the concept of the Fas counterattack. In a
replication study, FasL-expressing colon cancer cells did
not induce apoptosis in Fas-sensitive target cells [52]. In a
gene transfer experiment, Fas resistant colon cancer cells,
subcutaneously injected into mice, rapidly regressed upon
transfection with FasL [53]. In another experiment, cyto-
toxic T-cells were not sensitive to FasL displayed on the
surface of antigen-presenting cells [54]. Taken together, the
role of the Fas counterattack in colorectal carcinogenesis is
at least questionable [48].
In conclusion, we observed upregulation of FasL during
colorectal carcinogenesis, both in LS-associated and in
sporadic cases, without a correlation with the number of
TILs. Our data do not support an important role for the Fas
counterattack as a mechanism behind the difference between
colorectal carcinogenesis in LS-associated and sporadic
cases.
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